News | August 13, 2023
Aurobindo Pharma reports Q1 FY24 consolidated PAT at Rs. 570.75 Cr
Aurobindo Pharma has reported total income of Rs. 6966.85 crores during the period ended June 30, 2023
Aurobindo Pharma has reported total income of Rs. 6966.85 crores during the period ended June 30, 2023
The inspection closed with zero observations and a classification of No Action Indicated
Aurobindo will respond to the US FDA within the stipulated timelines
US formulations revenue increased by 11.6% YoY to Rs. 3,045 crore and Europe formulation revenue stood at Rs. 1,660 crore
The order marks a significant milestone for MMP Industries that will contribute to the company's revenue in the coming financial year
Company's Unit - IX, an API intermediate facility situated at Sangareddy District, Telangana, has now been classified as Voluntary Action Indicated
Revenue from operations during the quarter was up by 6.7 per cent to Rs 6,407.10 crore against Rs 6,002.2 in the same period last fiscal.
The company had responded to the agency and carried out the required corrective actions.
Formulation revenue decreased by 7.6% YoY to Rs. 4,770 crore whereas in Q2 FY23, API business posted a growth of 24.2% YoY with revenue of Rs. 969.4 crore
The Board also decided that Auro Vaccines will explore the possibilities of offering contract manufacturing to global vaccine developers
Subscribe To Our Newsletter & Stay Updated
